Type 1 diabetes is caused by the immune system mistakenly attacking and destroying the insulin-producing cells in the pancreas. This autoimmune destruction unfolds over months or years, and by the time symptoms appear, roughly 80% to 90% of those cells are already gone. What triggers the immune system to turn on itself involves a combination of inherited genetic risk and environmental factors, neither of which is fully sufficient on its own.
The Immune System Attacks the Pancreas
In a healthy body, the pancreas contains clusters of cells called islets, and within those islets are beta cells that produce insulin. In type 1 diabetes, certain immune cells, particularly a type of white blood cell called CD8+ T cells, infiltrate the islets and begin killing beta cells. This process is called insulitis, and it can simmer quietly for years before enough beta cells are lost to cause noticeable blood sugar problems.
CD8+ T cells appear to be the primary attackers. Research in both mice and humans shows they target proteins found only on beta cells, with fragments of the insulin molecule itself being a major target. Because insulin is produced exclusively by beta cells, this makes the attack highly specific. CD4+ T cells, another branch of the immune system, circulate in higher numbers around the time of diagnosis, but their direct role in killing beta cells is less clear. The end result is the same: without enough functioning beta cells, the body can no longer regulate blood sugar, and insulin must come from injections or a pump.
Genes Set the Stage
Genetics account for a large share of who develops type 1 diabetes, but they don’t seal anyone’s fate. The strongest genetic link comes from a region of DNA involved in how the immune system identifies friend from foe. This region, part of the major histocompatibility complex, is responsible for roughly 40% of the inherited risk for the disease. Specific gene variants called DR3 and DR4 are the most important. People who carry both (the DR3/4-DQ8 combination) have the single highest genetic risk.
How powerful is that combination? In one study tracking siblings of children with type 1 diabetes, those who carried the DR3/4-DQ8 genotype and shared both copies of the relevant gene region with their affected sibling had a 55% chance of developing diabetes by age 12. Siblings who shared zero or one copy had only a 5% chance. That’s an enormous difference driven entirely by which gene variants were inherited.
Still, genes are not destiny. Identical twins share all their DNA, yet when one twin has type 1 diabetes, the other develops it at most only half the time. Something beyond genetics is clearly required.
Family Risk by Relationship
The odds of a child developing type 1 diabetes depend on which parent is affected. A father with type 1 diabetes passes along roughly a 1 in 17 chance. A mother with type 1 diabetes passes along a 1 in 25 chance if the child is born before the mother turns 25, dropping to 1 in 100 if the child is born after that age. If both parents have the disease, the child’s risk jumps to between 1 in 10 and 1 in 4. For any parent, developing diabetes before age 11 roughly doubles the risk passed to offspring.
These numbers highlight an important reality: most children who develop type 1 diabetes do not have a parent with the condition. The genetic risk can be inherited from parents who carry the relevant gene variants without ever developing the disease themselves.
Viral Infections as a Trigger
Among environmental suspects, certain viruses stand out. Enteroviruses, particularly the Coxsackie B family, can directly infect beta cells in the pancreas. Once inside, these viruses replicate, reduce insulin production, disrupt the cell’s internal machinery, and can trigger cell death. Coxsackie B1 is considered one of the most destructive strains to human islet cells in laboratory studies, while Coxsackie B4 has been shown to impair glucose tolerance in animal models.
The connection goes beyond direct cell damage. When a virus infects beta cells, the immune system responds by attacking the infected cells. In someone with the right genetic predisposition, this response may not shut off properly. The immune system continues targeting beta cells long after the virus is cleared, essentially confusing the body’s own tissue for a lingering threat. A meta-analysis of 38 case-control studies found a consistent association between enterovirus infection and type 1 diabetes risk.
The Gut Microbiome and Early Life
The community of bacteria living in the gut appears to play a role in whether the immune system stays balanced or tips toward autoimmunity. Disruptions to this bacterial ecosystem, sometimes called dysbiosis, have gained attention as a possible contributing factor. Notably, changes in the gut microbiome seem to occur before the appearance of the autoantibodies that mark the earliest stages of type 1 diabetes, suggesting the shift in gut bacteria is part of the cause rather than a consequence.
Animal studies reinforce this idea. Giving antibiotics to young mice, which wipes out much of their gut bacteria, accelerates the onset of type 1 diabetes. This aligns with the broader hygiene hypothesis: that reduced microbial exposure in early life, whether from antibiotics, cleaner environments, or other modern factors, may leave the immune system more prone to attacking the body’s own tissues. The geographic pattern of the disease fits this theory. Northern Europe has the highest incidence among children under 14, at about 24 cases per 100,000, followed by Australia and New Zealand at roughly 23 per 100,000. Meanwhile, parts of Western Africa and South America see fewer than 1 case per 100,000. Genetics and ancestry explain part of this gap, but not all of it.
Vitamin D and Geography
The fact that type 1 diabetes is more common at higher latitudes, where sunlight is weaker and vitamin D production in the skin is lower, has long intrigued researchers. A study from the University of California, San Diego found a correlation between blood levels of vitamin D and subsequent incidence of type 1 diabetes. The researchers estimated that maintaining a blood level of 50 ng/ml of the circulating form of vitamin D could potentially prevent half of type 1 diabetes cases. That level is higher than what most people achieve without supplementation, particularly in northern climates during winter months.
This remains a correlation, not confirmed cause and effect, but vitamin D is known to play a role in regulating immune function. Low levels could plausibly contribute to the kind of immune dysregulation that allows autoimmune destruction to take hold.
Cow’s Milk Formula: A Theory Put to Rest
For years, some researchers suspected that exposing infants to cow’s milk proteins too early might trigger the autoimmune process. A major international trial called TRIGR tested this directly. Over 2,100 newborns with a family history of type 1 diabetes and confirmed genetic risk were randomly assigned to either standard cow’s milk formula or a formula where the proteins were pre-broken into tiny fragments. The children were followed for about 11 and a half years. The results: 7.6% of children on standard formula developed diabetes, compared to 8.4% on the modified formula. No meaningful difference. Current dietary recommendations for high-risk infants did not change as a result.
Autoantibodies and the Stages Before Diagnosis
Type 1 diabetes doesn’t appear overnight. The autoimmune process produces detectable warning signs in the blood: autoantibodies that target components of beta cells. Four major autoantibodies are tested for, each targeting a different protein involved in insulin production or beta cell function. A person with a single positive autoantibody has a low risk of progressing to diabetes, often less than 5%. But with two or more positive autoantibodies, the picture changes dramatically. Given 20 years of follow-up, nearly all children who express multiple autoantibodies eventually progress to clinical diabetes, whether they have a family history or not.
This understanding has led to a staging system. Stage 1 means two or more autoantibodies are present but blood sugar is still normal. Stage 2 means autoantibodies are present and blood sugar is beginning to rise abnormally. Stage 3 is full clinical diabetes with symptoms. This staging matters because it opened the door to the first preventive treatment: a drug approved by the FDA in 2022 for people aged 8 and older with stage 2 disease. In clinical trials, it delayed progression to stage 3 by a median of about two years (50 months versus 25 months with placebo). It doesn’t prevent type 1 diabetes, but it buys time before insulin dependence begins.
Why No Single Cause Explains It
Type 1 diabetes requires a collision of factors. A person needs genetic susceptibility, most powerfully from the DR3/4-DQ8 gene combination that shapes how the immune system works. They likely need an environmental trigger, whether a viral infection, a shift in gut bacteria, low vitamin D, or something not yet identified. And the autoimmune process must sustain itself long enough to destroy a critical mass of beta cells. Many people carry the high-risk genes and never develop the disease. Many encounter the same viruses without consequence. It’s the unlucky overlap, genes loading the gun and environment pulling the trigger, that leads to type 1 diabetes.